Amarin Corporation PLC
440 Route 22
466 articles with Amarin Corporation PLC
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
Amarin Corporation plc highlighted new in vitro data supporting the potential mechanistic effects of eicosapentaenoic acid in reducing cardiovascular events in at-risk patients presented at the joint ACC.23 together with the World Congress of Cardiology in New Orleans, LA, March 4-6, 2023.
Amarin Announces Board Departures - March 06, 2023
Amarin Corporation plc announced that, in the interest of the Company to avoid further proxy contests, all seven independent non-Sarissa board members: Adam Berger, Erin Enright, Geraldine Murphy, Kristine Peterson, Dr. Murray Stewart, Jan van Heek and Alfonso “Chito” Zulueta will resign from the Board of Directors, effective immediately.
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
Amarin Corporation plc announced a new analysis from the VASCEPA/VAZKEPA cardiovascular outcomes REDUCE-IT study showing the effectiveness of VASCEPA®/VAZKEPA® in patients with recent acute coronary syndrome.
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Amarin Corporation plc today announced financial results for the quarter and year ended December 31, 2022 and provided an update on the Company’s operations.
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
Amarin Corporation plc announced that, based on the preliminary voting results provided by its proxy solicitors following the Company’s 2023 General Meeting of Shareholders, Amarin shareholders have voted to elect all seven of Sarissa’s nominees and remove Per Wold-Olsen as Chairman of the Board of Directors, effective immediately.
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
Amarin Corporation plc (NASDAQ:AMRN) and CSL Seqirus today announced that the two companies have entered into an exclusive license and distribution agreement under which Amarin will license exclusive rights to VAZKEPA to CSL Seqirus to secure pricing and reimbursement and commercialize the product across Australia and New Zealand.
Amarin Sets the Record Straight on Sarissa’s Latest Misstatements
Amarin Corporation plc issued the following statement in response to Sarissa’s latest misstatements regarding the Company’s management compensation:
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCCPresentations on Additional REDUCE-IT® Sub-Population, In-Vitro Data on EPA to Be Featured at the Congress
Amarin Corporation plc (NASDAQ:AMRN) today announced that data evaluating the role of VASCEPA®/VAZKEPA® (icosapent ethyl) and eicosapentaenoic acid (EPA) in reducing cardiovascular events in at-risk patients will be presented at the joint ACC.23 together with the World Congress of Cardiology (ACC.23/WCC) in New Orleans, LA, March 4-6, 2023.
Amarin to Present at Cowen's 43rd Annual Health Care Conference
Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the Cowen Annual Health Care Conference.
Amarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023
Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s fourth quarter and year end 2022 financial results on Wednesday, March 1st, 2023 at 8:00 a.m. ET.
Amarin Clearly and Definitively Instructed Registrar to Accept ALL Submitted Proxy CardsSarissa Issued its False Release Hours After Receiving Confirmation That All Proxy Cards Were Being Accepted
Amarin Corporation plc corrected the record regarding the latest misinformation from Sarissa Capital Management.
Amarin Shareholders Invited to Webcast with Board and Management Team
Amarin Corporation plc announced that members of its Board of Directors and management team will host a live webcast on Tuesday, February 14, 2023, from 8:00 a.m. - 9:00 a.m. ET.
Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership
Amarin Corporation plc announced that it has mailed a letter to shareholders in connection with the General Meeting of Shareholders urging shareholders to vote “AGAINST” all proposals on the WHITE proxy card.
Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders
Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that it has filed definitive proxy materials with the Securities and Exchange Commission (“SEC”) in connection with its upcoming General Meeting of Shareholders scheduled to be held on February 28, 2023.
Amarin to Present at SVB Securities Global Biopharma Conference
Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the SVB Securities Global Biopharma Conference.
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand
Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe in New Zealand has granted approval to VAZKEPA (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in adult statin-treated patients with high CV risk with elevated triglycerides.
Amarin Corporation wrestled with activist investor Sarissa Capital Management as the latter tried to replace Amarin’s current board of directors with its representatives.
Amarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders
Amarin Corporation plc confirmed receipt of a requisition by Sarissa Capital Management LP to convene a General Meeting of Shareholders.
Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023
Amarin Corporation plc (NASDAQ:AMRN) today provided a business update, including preliminary fourth quarter and full-year 2022 revenue.
Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP
Amarin Corporation plc announced that Murray W. Stewart, D.M., F.R.C.P., has been appointed to the Company’s Board of Directors.